0000950123-21-006704.txt : 20210517 0000950123-21-006704.hdr.sgml : 20210517 20210517065832 ACCESSION NUMBER: 0000950123-21-006704 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 EFFECTIVENESS DATE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 21927472 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml 13F-HR LIVE 0001703031 XXXXXXXX 03-31-2021 03-31-2021 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P. The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of March 31, 2021, such persons held an aggregate of 8,525,000 shares of DVAX common stock. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of March 31, 2021, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of March 31, 2021, such persons held an aggregate of 4,350,000 shares of SYRS common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 05-17-2021 5 31 1765308 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 28-20816 Bain Capital Life Sciences Investors II, LLC 5 28-20814 Bain Capital Life Sciences Fund II, L.P. INFORMATION TABLE 2 4224.xml INFORMATION TABLE FOR FORM 13F DICERNA PHARMACEUTICALS INC COM 253031108 78762 3080237 SH SOLE 3080237 0 0 MARINUS PHARMACEUTICALS INC COM 56854Q200 22153 1431058 SH SOLE 1431058 0 0 SOLID BIOSCIENCES INC COM 83422E105 43852 7929918 SH SOLE 7929918 0 0 APTINYX INC COM 03836N103 26675 8891758 SH SOLE 8891758 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 429009 5831307 SH SOLE 5831307 0 0 DYNAVAX TECHNOLOGIES CORP COM 268158201 107105 10895773 SH SOLE 10895773 0 0 CONSTELLATION PHARMACEUTICALS, INC. COM 210373106 32746 1400000 SH SOLE 1400000 0 0 X4 PHARMACEUTICALS INC COM 98420X103 18249 2119540 SH SOLE 2119540 0 0 SAVARA INC COM 805111101 24175 11622598 SH SOLE 11622598 0 0 ARCUTIS BIOTHERAPEUTICS, INC. COM 03969K108 115121 3979292 SH SOLE 3979292 0 0 MERSANA THERAPEUTICS INC COM 59045L106 59796 3695667 SH SOLE 3695667 0 0 CRINETICS PHARMACEUTICALS INC COM 22663K107 16371 1071428 SH SOLE 1071428 0 0 AEGLEA BIOTHERAPEUTICS INC COM 00773J103 21384 2700000 SH SOLE 2700000 0 0 ANNEXON INC COM 03589W102 90247 3241628 SH SOLE 3241628 0 0 NURIX THERAPEUTICS, INC. COM 67080M103 39929 1284314 SH SOLE 1284314 0 0 KYMERA THERAPEUTICS INC. COM 501575104 18637 479605 SH SOLE 479605 0 0 THERAPEUTICS ACQUISITION CORP COM CL A 88339T103 10510 1000000 SH SOLE 1000000 0 0 ARYA SCIENCES ACQUISITION CORP III COM CL A G3166W106 13780 1000000 SH SOLE 1000000 0 0 BCTG ACQUISITION CORP COM 05492W103 5560 500000 SH SOLE 500000 0 0 SYROS PHARMACEUTICALS, INC. COM 87184Q107 43272 5785036 SH SOLE 5785036 0 0 ATEA PHARMACEUTICALS, INC. COM 04683R106 346767 5615659 SH SOLE 5615659 0 0 C4 THERAPEUTICS, INC. COM STK 12529R107 60745 1642209 SH SOLE 1642209 0 0 BCLS ACQUISITION CORP COM CL A G0904B105 5153 487500 SH SOLE 487500 0 0 JIYA ACQUISITION CORP COM CL A 47760M102 2952 300000 SH SOLE 300000 0 0 HELIX ACQUISITION CORP COM CL A G4444C102 2550 250000 SH SOLE 250000 0 0 FRAZIER LIFESCIENCES ACQUISITION CORP UNIT 12/09/2025 G3710A121 3048 300000 SH SOLE 300000 0 0 PHARVARIS N.V. COM N69605108 88993 3180601 SH SOLE 3180601 0 0 ARYA SCIENCES ACQUISITION CORP IV CL A G31659108 7331 700000 SH SOLE 700000 0 0 BLUEBIRD BIO, INC. COM 09609G100 16226 538179 SH SOLE 538179 0 0 OMEGA ALPHA SPAC CL A G6749V107 3960 400000 SH SOLE 400000 0 0 RESEARCH ALLIANCE CORP II COM CL A 760873109 10250 1000000 SH SOLE 1000000 0 0